{"organizations": [], "uuid": "ef8e1e6c2c2788f8072f2af3428d3581ac686500", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 20, "shares": 20, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2018/04/26/105161913-jaks_story_image1.1910x1000.jpg", "site_section": "", "section_title": "", "url": "https://www.cnbc.com/2018/04/26/abbvie-beats-quarterly-revenue-estimates-raises-earnings-forecast.html", "country": "US", "domain_rank": 767, "title": "AbbVie beats quarterly revenue estimates, raises earnings forecast", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-26T03:00:00.000+03:00", "replies_count": 0, "uuid": "ef8e1e6c2c2788f8072f2af3428d3581ac686500"}, "author": "Source", "url": "https://www.cnbc.com/2018/04/26/abbvie-beats-quarterly-revenue-estimates-raises-earnings-forecast.html", "ord_in_thread": 0, "title": "AbbVie beats quarterly revenue estimates, raises earnings forecast", "locations": [], "entities": {"persons": [{"name": "imbruvica", "sentiment": "none"}, {"name": "abbvie abbvie", "sentiment": "none"}, {"name": "abbvie", "sentiment": "none"}], "locations": [{"name": "humira", "sentiment": "none"}], "organizations": [{"name": "modern medicine abbvie", "sentiment": "negative"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "AbbVie's first-quarter revenue beat analysts' estimates on Thursday on higher sales of its rheumatoid arthritis drug Humira and cancer treatment Imbruvica, while raising full-year earnings forecast.\nThe company's net revenue rose 21.4 percent to $7.93 billion, ahead of the average estimate of $7.59 billion, according to Thomson Reuters.\nSales of Humira, which account for nearly two-thirds of the company's total revenue, rose to $4.71 billion, beating estimates of $4.64 billion.\nImbruvica raked in $762 million in sales, above expectations of $755.77 million.\nThe drugmaker raised its 2018 adjusted earnings per share expectation to between $7.66 and $7.76, from between $7.33 and $7.43 previously forecast.\nThe forecast accounts for an effective tax rate approaching 9 percent this year, AbbVie said.\nNet earnings rose to $2.78 billion, or $1.74 per share, in the three months ended March 31, from $1.71 billion, or $1.06 per share, a year earlier.\nExcluding items, AbbVie earned $1.87 per share.", "external_links": [], "published": "2018-04-26T03:00:00.000+03:00", "crawled": "2018-04-26T16:52:03.009+03:00", "highlightTitle": ""}